Table 1

Baseline characteristics in the study population as a whole, stratified by postablation response in LVEF (>7.5%)

VariablesAll patients, n=52LVEF improved, n=30LVEF
not improved, n=22
P value*
Age (years)63±863±862±70.83
Male (%)1001001001.00
LVEF (%)36±836±836±90.70
Hypertension (%)8373950.04
Diabetes mellitus (%)121390.64
COPD (%)2120230.81
OSA (%)3523500.05
Prior MI (%)1510230.21
Ischaemic heart disease (%)4237500.34
CHA2DS2VASc score2.6±12.4±13.0±10.13
CRT or ICD (%)127180.24
Body mass index (kg/m2)31±629±532±70.08
Persistent/long-standing AF (%)6057640.62
 Beta blocker (%)8583860.76
 ACEi/ARB (%)6760770.19
 Spironolactone (%)1713230.38
 Hydralazine and ISDN (%)2050.24
 Digoxin (%)2930270.83
 Diuretics (%)3733410.58
 Antiarrhythmic (%)4440500.47
 Heart rate (bpm)93±2097±2289±160.15
 Corrected R-R dispersion (ms)600±162645±155537±1540.02
 LVIDd (mm)58±854±658±80.03
 LVIDs (mm)44±842±746±90.06
 LAD (mm)49±948±950±80.18
 Valvular (%)127180.20
  • *Improved (ΔLVEF >7.5%) versus not improved.

  • ACEi, ACE inhibitor;AF, atrial fibrillation;ARB, angiotensin receptor blocker;COPD, chronic obstructive pulmonary disease;CRT, Cardiac Resynchronization Therapy; ICD, implantable cardioverter defibrillator;ISDN, isosorbide dinitrate;LVEF, left ventricular ejection fraction;LVIDd, left ventricular internal diameter during end-diastole; LVIDs, left ventricular internal diameter during end-systole; MI, myocardial infarction;OSA, obstructive sleep apnoea; bpm, beats per minute.